Limits...
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.

Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T - Br. J. Cancer (2002)

Bottom Line: We found that cimetidine treatment was particularly effective in patients whose tumour had higher sL(x) and sL(a) antigen levels.In contrast, in the group of patients with no or low levels CSLEX staining, cimetidine did not show significant beneficial effect (the 10-year survival rate of the cimetidine group was 70.0% and that of control group was 85.7% (P=n.s.)).These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumour cells expressing high levels of sL(x) and sL(a).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 3-6-10 Otohbashi, Nakagawa-ku, Nagoya 454-8509, Japan. smatsumo@fujita-hu.ac.jp

Show MeSH

Related in: MedlinePlus

Effect of cimetidine on cumulative survival rates in the colorectal cancer patients. The tumour tissues from individual patients obtained during curative operations were stained by mAbs to sLx antigen, including CSLEX (A), KM93 (B), FH6 (C) and sLa antigen, CA19-9 (D). The level of these epitope expression were semi-quantitated upon microscopic examination by two experienced pathologists: level 1, less than 5% cancer cells stained; level 2, 5–70% cancer cells stained; level 3, 71% or more cancer cells stained. The survival rates of patients with cimetidine treatment (‘Cimetidine’) or without cimetidine treatment (‘Control’) were compared using Kaplan-Meier method. The number of patients (‘n’) in each category was indicated in the figure. The statistical significance was evaluated by log rank test and generalized Wilcoxon test.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375187&req=5

fig3: Effect of cimetidine on cumulative survival rates in the colorectal cancer patients. The tumour tissues from individual patients obtained during curative operations were stained by mAbs to sLx antigen, including CSLEX (A), KM93 (B), FH6 (C) and sLa antigen, CA19-9 (D). The level of these epitope expression were semi-quantitated upon microscopic examination by two experienced pathologists: level 1, less than 5% cancer cells stained; level 2, 5–70% cancer cells stained; level 3, 71% or more cancer cells stained. The survival rates of patients with cimetidine treatment (‘Cimetidine’) or without cimetidine treatment (‘Control’) were compared using Kaplan-Meier method. The number of patients (‘n’) in each category was indicated in the figure. The statistical significance was evaluated by log rank test and generalized Wilcoxon test.

Mentions: The effect of cimetidine on the survival of patients was evaluated with regard to the level of sLx and sLa antigens. The cumulative survival rates of patients, with or without cimetidine, based on the CSLEX epitope expression were demonstrated in Figure 3AFigure 3


Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.

Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T - Br. J. Cancer (2002)

Effect of cimetidine on cumulative survival rates in the colorectal cancer patients. The tumour tissues from individual patients obtained during curative operations were stained by mAbs to sLx antigen, including CSLEX (A), KM93 (B), FH6 (C) and sLa antigen, CA19-9 (D). The level of these epitope expression were semi-quantitated upon microscopic examination by two experienced pathologists: level 1, less than 5% cancer cells stained; level 2, 5–70% cancer cells stained; level 3, 71% or more cancer cells stained. The survival rates of patients with cimetidine treatment (‘Cimetidine’) or without cimetidine treatment (‘Control’) were compared using Kaplan-Meier method. The number of patients (‘n’) in each category was indicated in the figure. The statistical significance was evaluated by log rank test and generalized Wilcoxon test.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375187&req=5

fig3: Effect of cimetidine on cumulative survival rates in the colorectal cancer patients. The tumour tissues from individual patients obtained during curative operations were stained by mAbs to sLx antigen, including CSLEX (A), KM93 (B), FH6 (C) and sLa antigen, CA19-9 (D). The level of these epitope expression were semi-quantitated upon microscopic examination by two experienced pathologists: level 1, less than 5% cancer cells stained; level 2, 5–70% cancer cells stained; level 3, 71% or more cancer cells stained. The survival rates of patients with cimetidine treatment (‘Cimetidine’) or without cimetidine treatment (‘Control’) were compared using Kaplan-Meier method. The number of patients (‘n’) in each category was indicated in the figure. The statistical significance was evaluated by log rank test and generalized Wilcoxon test.
Mentions: The effect of cimetidine on the survival of patients was evaluated with regard to the level of sLx and sLa antigens. The cumulative survival rates of patients, with or without cimetidine, based on the CSLEX epitope expression were demonstrated in Figure 3AFigure 3

Bottom Line: We found that cimetidine treatment was particularly effective in patients whose tumour had higher sL(x) and sL(a) antigen levels.In contrast, in the group of patients with no or low levels CSLEX staining, cimetidine did not show significant beneficial effect (the 10-year survival rate of the cimetidine group was 70.0% and that of control group was 85.7% (P=n.s.)).These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumour cells expressing high levels of sL(x) and sL(a).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 3-6-10 Otohbashi, Nakagawa-ku, Nagoya 454-8509, Japan. smatsumo@fujita-hu.ac.jp

Show MeSH
Related in: MedlinePlus